Investors and Media
Our mission as a biotechnology company is to research, develop and commercialize a next-generation of small molecule cancer therapeutics. We are combining innovative, proprietary anti-cancer technology with world-class chemistry capabilities to generate drug candidates that target multiple tumor types, act selectively against cancer cells and are well tolerated by patients. Our lead products are in clinical development, and our research pipeline targets multiple molecules with established roles and therapeutic potential in cancer.
We are headquartered and operate research facilities and development programs in Woburn, Massachusetts.
Recent Releases
Mar 4, 2010
ArQule, Inc. to Present at Cowen and Company Health Care Conference
Mar 2, 2010
ArQule Reports Fiscal 2009 Year End and Fourth Quarter Results
Events & Presentations
Mar 2, 2010 at 9:00 AM ET
Q4 2009 ArQule, Inc. Earnings Conference Call
Mar 9, 2010
Corporate Presentation
| Stock Chart | Stock Quote | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||||||||
Transfer Agent
American Stock and Transfer
41 Wall Street
New York City, NY 10005
Phone: 212-936-5100
Public Financings - Facts at a Glance
| IPO date: | October 16, 1996 |
|---|---|
| IPO offering price: | $12.00 |
| IPO total gross proceeds: | $34 million |
| IPO shares sold: | 2.88 million |
| High since IPO: | $40.38 (2/17/00) |
| Low since IPO: | $1.92 (3/10/03) |
| Follow-on offering date: | April 4, 1997 |
| Follow-on offering price: | $12.00 |
| Follow-on total gross proceeds: | $24 million |
| Follow-on shares sold: | 2 million |
| Follow-on offering date: | November 21, 2000 |
| Follow-on offering price: | $22.50 |
| Follow-on total gross proceeds: | $76 million |
| Follow-on shares sold: | 3,358,000 |
| Follow-on offering date: | January 28, 2005 |
| Follow-on offering price: | $5.25 |
| Follow-on total gross proceeds: | $30 million |
| Follow-on shares sold: | 5,790,000 |
| Follow-on offering date: | June 19, 2007 |
| Follow-on offering price: | $7.75 |
| Follow-on total gross proceeds: | $58 million |
| Follow-on shares sold: | 7,502,000 |




